Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Parrott

Showing results (51-60 of 125) with videos related to

Pageof 13
Sort By:
European Thyroid Journal|May 1, 2014
Use of Pre-Ablation Radioiodine-131 Scan to Assess the Impact of Surgical Volume and Specialisation following Thyroidectomy for Differentiated Thyroid CarcinomaBeng Khiong Yap, Jarrod Homer, Neil Parrott, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 9, 2016
Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction MetabolizedStephen Fowler, Elena Guerini, NaHong Qiu, et al.
Drug Metabolism and Pharmacokinetics|January 7, 2026
Current status of prediction of IL-6 mediated cytochrome P450 activity modulation using in vitro data and PBPK modelingViktor Georgiev, Isabelle Anderka, Delia Bucher, et al.
Clinical Pharmacokinetics|June 5, 2018
The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic ModellingJustine Badée, Stephen Fowler, Saskia N de Wildt, et al.
Clinical Pharmacokinetics|April 18, 2013
Physiologically based pharmacokinetic modelling to predict single- and multiple-dose human pharmacokinetics of bitopertinNeil Parrott, Dominik Hainzl, Daniela Alberati, et al.
Clinical Pharmacokinetics|June 16, 2023
The Activity of Members of the UDP-Glucuronosyltransferase Subfamilies UGT1A and UGT2B is Impaired in Patients with Liver CirrhosisUrs Duthaler, Fabio Bachmann, Agustos C Ozbey, et al.
The AAPS Journal|June 28, 2014
Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertinNeil Parrott, Dominik Hainzl, Emmanuel Scheubel, et al.
Lab on a Chip|July 14, 2022
Application of a gut-liver-on-a-chip device and mechanistic modelling to the quantitative <i>in vitro</i> pharmacokinetic study of mycophenolate mofetilNicoló Milani, Neil Parrott, Daniela Ortiz Franyuti, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 31, 2025
Middle-Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for AlectinibTamara van Donge, Elena Guerini, Amaury O'Jeanson, et al.
Clinical Pharmacology and Therapeutics|February 25, 2020
Real-World Data and Physiologically-Based Mechanistic Models for Precision MedicineKen Wang, Neil Parrott, Andres Olivares-Morales, et al.
Pageof 13

Showing results (51-60 of 125) with videos related to

Sort By:
Pageof 13
European Thyroid Journal|May 1, 2014
Use of Pre-Ablation Radioiodine-131 Scan to Assess the Impact of Surgical Volume and Specialisation following Thyroidectomy for Differentiated Thyroid CarcinomaBeng Khiong Yap, Jarrod Homer, Neil Parrott, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 9, 2016
Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction MetabolizedStephen Fowler, Elena Guerini, NaHong Qiu, et al.
Drug Metabolism and Pharmacokinetics|January 7, 2026
Current status of prediction of IL-6 mediated cytochrome P450 activity modulation using in vitro data and PBPK modelingViktor Georgiev, Isabelle Anderka, Delia Bucher, et al.
Clinical Pharmacokinetics|June 5, 2018
The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic ModellingJustine Badée, Stephen Fowler, Saskia N de Wildt, et al.
Clinical Pharmacokinetics|April 18, 2013
Physiologically based pharmacokinetic modelling to predict single- and multiple-dose human pharmacokinetics of bitopertinNeil Parrott, Dominik Hainzl, Daniela Alberati, et al.
Clinical Pharmacokinetics|June 16, 2023
The Activity of Members of the UDP-Glucuronosyltransferase Subfamilies UGT1A and UGT2B is Impaired in Patients with Liver CirrhosisUrs Duthaler, Fabio Bachmann, Agustos C Ozbey, et al.
The AAPS Journal|June 28, 2014
Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertinNeil Parrott, Dominik Hainzl, Emmanuel Scheubel, et al.
Lab on a Chip|July 14, 2022
Application of a gut-liver-on-a-chip device and mechanistic modelling to the quantitative <i>in vitro</i> pharmacokinetic study of mycophenolate mofetilNicoló Milani, Neil Parrott, Daniela Ortiz Franyuti, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 31, 2025
Middle-Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for AlectinibTamara van Donge, Elena Guerini, Amaury O'Jeanson, et al.
Clinical Pharmacology and Therapeutics|February 25, 2020
Real-World Data and Physiologically-Based Mechanistic Models for Precision MedicineKen Wang, Neil Parrott, Andres Olivares-Morales, et al.
Pageof 13